CN108472312A - 用于增加睑板腺脂质分泌物的含硫醇及二硫化物的药剂 - Google Patents

用于增加睑板腺脂质分泌物的含硫醇及二硫化物的药剂 Download PDF

Info

Publication number
CN108472312A
CN108472312A CN201680069405.8A CN201680069405A CN108472312A CN 108472312 A CN108472312 A CN 108472312A CN 201680069405 A CN201680069405 A CN 201680069405A CN 108472312 A CN108472312 A CN 108472312A
Authority
CN
China
Prior art keywords
lipid
acid
agent
meibomian glands
disulfide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680069405.8A
Other languages
English (en)
Chinese (zh)
Inventor
希蒙·艾姆萨勒姆
亚伊尔·阿尔斯特
多伦·弗里德曼
奥默·拉法尔里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mg Therapeutics Ltd
Original Assignee
Mg Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mg Therapeutics Ltd filed Critical Mg Therapeutics Ltd
Priority to CN202110338196.5A priority Critical patent/CN113144203B/zh
Publication of CN108472312A publication Critical patent/CN108472312A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680069405.8A 2015-09-28 2016-09-28 用于增加睑板腺脂质分泌物的含硫醇及二硫化物的药剂 Pending CN108472312A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110338196.5A CN113144203B (zh) 2015-09-28 2016-09-28 用于增加睑板腺脂质分泌物的含硫醇及二硫化物的药剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562233941P 2015-09-28 2015-09-28
US201562233906P 2015-09-28 2015-09-28
US62/233,941 2015-09-28
US62/233,906 2015-09-28
PCT/IB2016/001510 WO2017055924A2 (en) 2015-09-28 2016-09-28 Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110338196.5A Division CN113144203B (zh) 2015-09-28 2016-09-28 用于增加睑板腺脂质分泌物的含硫醇及二硫化物的药剂

Publications (1)

Publication Number Publication Date
CN108472312A true CN108472312A (zh) 2018-08-31

Family

ID=58408743

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680069405.8A Pending CN108472312A (zh) 2015-09-28 2016-09-28 用于增加睑板腺脂质分泌物的含硫醇及二硫化物的药剂
CN202110338196.5A Active CN113144203B (zh) 2015-09-28 2016-09-28 用于增加睑板腺脂质分泌物的含硫醇及二硫化物的药剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110338196.5A Active CN113144203B (zh) 2015-09-28 2016-09-28 用于增加睑板腺脂质分泌物的含硫醇及二硫化物的药剂

Country Status (9)

Country Link
US (3) US10688122B2 (https=)
EP (1) EP3313413B1 (https=)
JP (2) JP2018533622A (https=)
KR (1) KR20180090251A (https=)
CN (2) CN108472312A (https=)
AU (1) AU2016332966A1 (https=)
CA (1) CA3000088A1 (https=)
ES (1) ES3007759T3 (https=)
WO (1) WO2017055924A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110719775A (zh) * 2017-03-29 2020-01-21 阿祖拉眼科有限公司 用于增加睑板腺脂质分泌的药剂

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022066A1 (en) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
US10688122B2 (en) * 2015-09-28 2020-06-23 Azura Ophthalmics Ltd. Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
US11040062B2 (en) 2016-04-14 2021-06-22 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
AU2018385766B2 (en) 2017-12-15 2022-12-01 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
WO2020092402A1 (en) * 2018-10-30 2020-05-07 Harrow Health, Inc. Pharmaceutical compositions of tiopronin and methods for preparing thereof
US12239644B2 (en) * 2018-11-02 2025-03-04 Kyungpook National University Industry-Academic Cooperation Foundation Composition for prevention or treatment of macular degeneration
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
JP7723603B2 (ja) * 2019-04-12 2025-08-14 アズーラ オフサルミックス エルティーディー． コンタクトレンズ不快感を処置するための組成物および方法
WO2021090070A2 (en) * 2019-11-04 2021-05-14 Azura Ophthalmics Ltd. Metered dose for disorders in or around the eye
JP2023513415A (ja) 2020-01-02 2023-03-31 アズーラ オフサルミックス エルティーディー． 二硫化セレン組成物の製造
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
EP4232034A4 (en) * 2020-10-21 2024-12-04 Azura Ophthalmics Ltd COMPOUNDS AND METHODS FOR TREATING EYE DISORDERS
US12286451B2 (en) 2020-11-23 2025-04-29 Medtech Products Inc. Borate ester complexes of α-hydroxy carboxylic acids and their conjugate base buffers
US20220160668A1 (en) 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
CN112569179B (zh) * 2020-12-25 2022-12-27 上海交通大学医学院附属第九人民医院 一种可注射水凝胶体系及其制备方法
WO2023215244A1 (en) * 2022-05-02 2023-11-09 Georgetown University Use of n-acetylcysteine to treat lipid disorders and related organ dysfunctions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153607A (en) * 1995-12-04 2000-11-28 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance (or turnover)
WO2007070463A2 (en) * 2005-12-12 2007-06-21 Riolan Technologies, Inc. Compositions, methods and kits for removing debris from an ocular area
US20090238810A1 (en) * 2006-11-30 2009-09-24 Menicon Co., Ltd. Ophthalmic composition
US20110104206A1 (en) * 2009-10-30 2011-05-05 Intratus, Inc. Methods and compositions for sustained delivery of drugs
WO2013003731A2 (en) * 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236730A (en) 1962-01-04 1966-02-22 Miles Lab Blepharitis composition comprising antiseptic, quaternary ammonium compound, keratolytic agent and a chelating compound
US5602130A (en) 1987-03-20 1997-02-11 Allergan Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
JP2891883B2 (ja) * 1993-11-05 1999-05-17 学校法人近畿大学 抗白内障医薬組成物
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
EP0930072A1 (en) 1998-01-13 1999-07-21 Kartar Dr. Lalvani Vitamin and mineral containing compositions for the treatment of dry eye
US6348508B1 (en) 2000-04-04 2002-02-19 Bausch & Lomb Incorporated Method for treating dry eye
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
FR2833268B1 (fr) 2001-12-12 2005-07-08 Fabre Pierre Dermo Cosmetique Nouvelle association contenant un poloxamer et de l'acide chondroitine sulfurique et/ou une glycoproteine et son utilisation
KR100564386B1 (ko) 2002-05-13 2006-03-27 주식회사 마이코플러스 4-하이드록시-5-메톡시-4-[2-메틸-3-(3-메틸-2-부테닐)-2-옥시란닐]-1-옥사스피로[2,5]옥탄-6-온을 함유한 지루치료용 약제학적 조성물
US8420699B1 (en) 2002-06-19 2013-04-16 Irvine L. Dubow Composition and methods of treatment using deionized and ozonated solution
EP1531793A1 (en) 2002-07-23 2005-05-25 Novartis AG Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
EP2272340B1 (en) 2002-08-19 2018-03-14 Ira Sanders Botulinum toxin
US20040171561A1 (en) 2002-09-03 2004-09-02 Popp Karl F. Topical formulations for treatment of rosacea
EP1551399A4 (en) 2002-09-30 2011-01-05 Mark A Babizhayev METHOD FOR THE TOPICAL TREATMENT OF EYE DISEASES AND COMPOSITION AND DEVICE FOR THIS TREATMENT
US20060188471A1 (en) 2002-10-31 2006-08-24 Podolsky Daniel K Methods of treating epithelial lesions
GB0225795D0 (en) 2002-11-05 2002-12-11 Guillon Michael Wipes
US20070269537A1 (en) 2003-02-10 2007-11-22 Bioderm Research Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
US20050197614A1 (en) 2004-03-04 2005-09-08 Wilson Pritchard Occlusive biomedical devices, punctum plugs, and methods of use thereof
US8455016B2 (en) 2004-03-12 2013-06-04 Melbj Holdings, Llc Treatment for meibomian gland dysfunction or obstruction
US20050202097A1 (en) 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
EP1621191A1 (en) 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
US20090214676A1 (en) 2005-04-30 2009-08-27 Tissuetech, Inc. Method for treating ocular demodex
CN101203236A (zh) * 2005-06-22 2008-06-18 坪田一男 角结膜疾病的预防或治疗剂
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US8083787B2 (en) 2005-07-18 2011-12-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
CA2651815A1 (en) 2006-05-10 2007-11-22 Dxterity Diagnostics Detection of nucleic acid targets using chemically reactive oligonucleotide probes
WO2007137369A1 (en) 2006-05-31 2007-12-06 Medihoney Pty Ltd Medicinal compositions containing honey
WO2008027069A1 (en) 2006-08-21 2008-03-06 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid
US8249695B2 (en) 2006-09-29 2012-08-21 Tearscience, Inc. Meibomian gland imaging
US8090426B2 (en) 2006-10-27 2012-01-03 Felder Robin A Microelectronic biosensor plug
US20100204317A1 (en) 2006-11-03 2010-08-12 Qlt Inc. Methods of treating dermatological disorders or conditions
BRPI0808410A2 (pt) * 2007-02-28 2015-06-23 Aciex Therapeutics Inc Métodos e composições para normalizar secreções da glândula meibomiana
US8128968B2 (en) 2007-08-29 2012-03-06 Tissuetech, Inc. Compositions and methods for treating Demodex infestations
ES2667945T3 (es) 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
WO2009120881A1 (en) * 2008-03-26 2009-10-01 Eric Donnenfeld Methods for improving lid margin and tear film function and treatment of lid margin desease using tetracycline family antibiotics
CN104623741A (zh) 2008-04-30 2015-05-20 马缇医疗股份有限公司 复合泪管植入物及相关方法
JP5661035B2 (ja) 2008-07-10 2015-01-28 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼および皮膚の疾患および症状の治療用のシクロスポリン誘導体
WO2010033800A2 (en) 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Tetracycline stabilizing formulations
CA2760591C (en) 2009-05-01 2018-01-02 Advanced Vision Research, Inc. Cleanser compositions and methods for using the same
CN101612161A (zh) 2009-08-07 2009-12-30 魏谠全 一种眼药组合物及其制剂
US20110294897A1 (en) 2009-12-02 2011-12-01 Bridge Pharma, Inc. Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion
US20120093876A1 (en) 2010-10-13 2012-04-19 Aciex, Inc. Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions
AU2011327785A1 (en) 2010-11-08 2013-03-07 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
WO2012092378A1 (en) 2010-12-29 2012-07-05 Inspire Pharmaceuticals, Inc. Method for treating blepharitis
WO2012092320A2 (en) 2010-12-29 2012-07-05 Nichamin Louis D Eye treatment
US20130281390A1 (en) 2010-12-29 2013-10-24 Kurt E. Brubaker Method for treating dry eye
KR101914940B1 (ko) 2011-01-26 2018-11-06 알러간, 인코포레이티드 안과 질환을 치료하기 위한 안드로겐 조성물
EP2711374A4 (en) 2011-05-20 2014-05-21 Univ Keio NEW METAL PROTEIN AND METHOD FOR THE PRODUCTION THEREOF, AND PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST HORN OR BINDING DAMAGE WITH THIS METAL PROTEIN
ITFI20120044A1 (it) 2012-03-01 2013-09-02 Biodue Spa Formulazione ad uso oftalmico comprendente olio di jojoba.
EP2838547B1 (en) * 2012-04-16 2019-09-04 Lubrizol Advanced Materials, Inc. Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions
US9238018B2 (en) * 2012-11-20 2016-01-19 Revive Therapeutics Inc. Use of bucillamine in the treatment of gout
US9211397B2 (en) * 2012-12-19 2015-12-15 Senju Usa, Inc. Patch for treatment of eyelid disease containing clobetasol
US9987235B2 (en) * 2013-08-01 2018-06-05 Nicholas L. Abbott Methods and compositions for modifying mucous membranes
HUE14755117T2 (hu) 2013-08-14 2018-12-28 Kalvista Pharmaceuticals Ltd Plazma-kallikrein inhibitorok
EP3139903B1 (en) 2014-05-07 2019-07-03 Croma-Pharma Gesellschaft m.b.H. Aqueous ophthalmic solution and method for treating dry eye syndrome
US9668996B2 (en) * 2014-06-04 2017-06-06 Tersus Life Sciences, LLC Methods of treating chronic dry eye disease using C16:1n7-palmitoleate and derivatives thereof
US9463201B2 (en) * 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
US10688122B2 (en) 2015-09-28 2020-06-23 Azura Ophthalmics Ltd. Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
US11040062B2 (en) * 2016-04-14 2021-06-22 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
JP2019513775A (ja) * 2016-04-19 2019-05-30 アズーラ オフサルミックス エルティーディー． 角化症の処置のための組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153607A (en) * 1995-12-04 2000-11-28 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance (or turnover)
WO2007070463A2 (en) * 2005-12-12 2007-06-21 Riolan Technologies, Inc. Compositions, methods and kits for removing debris from an ocular area
US20090238810A1 (en) * 2006-11-30 2009-09-24 Menicon Co., Ltd. Ophthalmic composition
US20110104206A1 (en) * 2009-10-30 2011-05-05 Intratus, Inc. Methods and compositions for sustained delivery of drugs
WO2013003731A2 (en) * 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AKYOL-SALMAN，等: "Efficacy of Topical N-Acetylcysteine in the Treatment of Meibomian Gland Dysfunction", 《JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110719775A (zh) * 2017-03-29 2020-01-21 阿祖拉眼科有限公司 用于增加睑板腺脂质分泌的药剂

Also Published As

Publication number Publication date
EP3313413A4 (en) 2018-07-11
US10688122B2 (en) 2020-06-23
EP3313413B1 (en) 2024-12-04
JP7138694B2 (ja) 2022-09-16
US20200179440A1 (en) 2020-06-11
CA3000088A1 (en) 2017-04-06
US20170087179A1 (en) 2017-03-30
ES3007759T3 (en) 2025-03-20
KR20180090251A (ko) 2018-08-10
WO2017055924A3 (en) 2017-07-06
WO2017055924A2 (en) 2017-04-06
EP3313413A2 (en) 2018-05-02
CN113144203B (zh) 2025-01-28
CN113144203A (zh) 2021-07-23
JP2018533622A (ja) 2018-11-15
AU2016332966A1 (en) 2018-04-26
JP2021063083A (ja) 2021-04-22
EP3313413C0 (en) 2024-12-04
US20220226367A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
JP7138694B2 (ja) マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤
KR102541236B1 (ko) 마이봄샘 지질 분비 증가를 위한 작용제
KR102350869B1 (ko) 마이봄샘 기능부전의 치료를 위한 조성물 및 방법
US20070082017A1 (en) Lipid compositions and methods of use
CN106455563A (zh) 硫辛酸胆碱酯组合物及使用方法
BR112020008046A2 (pt) composições e métodos de uso para tratamento de inflamação anormal em glândulas secretoras perioculares ou na superfície ocular
AU2024205420B2 (en) Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
HK1254414A1 (en) Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1254414

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180831

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1254414

Country of ref document: HK